Business Wire

Xerox Adaptive CMYK+ Kit for Xerox Versant Expands Color Palette to More Than a Million

7.7.2020 15:00:00 EEST | Business Wire | Press release

Share

Xerox announced the Xerox Adaptive CMYK+ Kit for Xerox Versant®, the print market’s first adaptive technology kit that adds seven specialty colors to an existing production press, enabling instant digital print enhancements. The kit transforms a four-color Xerox Versant® 180 Press into an 11-color Beyond CMYK press capable of creating a million color hues and shades by adding gold, silver, white, clear and fluorescent colors of yellow, magenta and cyan.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200707005242/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The print market’s first adaptive technology kit that adds seven specialty colors to an existing production press. (Photo: Business Wire)

Digital enhancement of print is projected to be a $25 billion market¹, but access to that opportunity usually requires a capital investment in a new press with the ability to print Beyond CMYK. The Xerox Adaptive CMYK+ Kit for Versant gives print providers the ability to simply swap out toners to print colors and enhancements that increase profitability and deliver higher margins without needing a new press.

“The Versant CMYK+ Adaptive Kit delivers what print providers need – the ability to provide higher value offerings without major investment,” says Marybeth Gilbert, vice president and general manager, Production Business, Xerox. “The Versant kit further expands Xerox’s market leading Beyond CMYK portfolio, providing our customers opportunity for digital print enhancements from large volume print shop, to light production and into the office space.”

According to Keypoint Intelligence, print providers can increase profit margins on digital enhancements between 50 and 400 percent versus ordinary print. Also, promotional printing such as marketing collateral, brochures, business cards, and signage is the most common application category for embellishments². The Versant 180 is uniquely suited and designed for such uses so print providers can easily convert, enhance and charge more for ordinary jobs.

The Xerox Adaptive CMYK+ Kit for Xerox Versant has three options: the Xerox Vivid Kit (gold, silver, white and clear), Xerox Fluorescent Kit (cyan, magenta and yellow) – or the combination Xerox Vivid + Fluorescent Kit for all 11 colors. The adaptive kit works with EFI DFE versions of the Versant 180 and Versant 180 with Performance Package.

Availability:
The Xerox Adaptive CMYK+ Kit for Xerox Versant is available now for order taking in both EMEA and the Americas. The kit will be available for delivery in EMEA on July 15, 2020 and in the Americas on August 17, 2020.

About Xerox
Xerox Holdings Corporation makes every day work better.
We are a workplace technology company building and integrating software and hardware for enterprises large and small. As customers seek to manage information across digital and physical platforms, Xerox delivers a seamless, secure and sustainable experience. Whether inventing the copier, Ethernet, the laser printer or more, Xerox has long defined the modern work experience. Learn how that innovation continues at xerox.com.

¹ Keypoint Intelligence/Infotrends, “Beyond CMYK: The Use of Special Effects in Digital Printing”
² Keypoint Intelligence/Infotrends, “Market Opportunities for CMYK+”

Note: To receive RSS news feeds, visit https://www.news.xerox.com. For open commentary, industry perspectives and views, visit http://twitter.com/xerox , http://www.facebook.com/XeroxCorp, https://www.instagram.com/xerox/, http://www.linkedin.com/company/xerox, http://www.youtube.com/XeroxCorp.

Xerox® is a trademark of Xerox in the United States and/or other countries.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Gary Walker, Xerox, +1-585-427-1679, Gary.Walker@xerox.com

Sonia Panchal, Xerox, +44 (0)7713 191581, sonia.panchal@xerox.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye